{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:21:53Z","timestamp":1788326513697,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":102,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Joint Funds for the Innovation of Science and Technology, Fujian Province","award":["2023Y9312"],"award-info":[{"award-number":["2023Y9312"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J011162"],"award-info":[{"award-number":["2023J011162"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Startup Fund for Scientific Research, Fujian Medical University","award":["2020QH1141"],"award-info":[{"award-number":["2020QH1141"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03626-1","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T01:04:51Z","timestamp":1779498291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer"],"prefix":"10.1186","volume":"27","author":[{"given":"Jie","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani C.","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"1","key":"3626_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","volume":"26","author":"A Drilon","year":"2020","unstructured":"Drilon A, Clark JW, Weiss J, Ou S-HI, Camidge DR, Solomon BJ, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47\u201351.","journal-title":"Nat Med"},{"issue":"9","key":"3626_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1159\/000525188","volume":"100","author":"W Shalata","year":"2022","unstructured":"Shalata W, Yakobson A, Weissmann S, Oscar E, Iraqi M, Kian W, et al. Crizotinib in MET Exon 14-Mutated or MET-Amplified in advanced disease non-small cell lung cancer: a retrospective single institution experience. Oncology. 2022;100(9):467\u201374.","journal-title":"Oncology"},{"issue":"13","key":"3626_CR3","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/1759-7714.14848","volume":"14","author":"K Miao","year":"2023","unstructured":"Miao K, Zhang X, Wang H, Si X, Zhang L. Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer. Thorac Cancer. 2023;14(13):1162\u201370.","journal-title":"Thorac Cancer"},{"issue":"10","key":"3626_CR4","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","volume":"9","author":"S Lu","year":"2021","unstructured":"Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med. 2021;9(10):1154\u201364.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"3626_CR5","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1097-2765(01)00378-1","volume":"8","author":"P Peschard","year":"2001","unstructured":"Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, et al. Mutation of the c-Cbl TKB domain binding site on the met receptor tyrosine kinase converts it into a transforming protein. Mol Cell. 2001;8(5):995\u20131004.","journal-title":"Mol Cell"},{"issue":"28","key":"3626_CR6","doi-asserted-by":"publisher","first-page":"29565","DOI":"10.1074\/jbc.M403954200","volume":"279","author":"P Peschard","year":"2004","unstructured":"Peschard P, Ishiyama N, Lin T, Lipkowitz S, Park M. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl\/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation*. J Biol Chem. 2004;279(28):29565\u201371.","journal-title":"J Biol Chem"},{"issue":"9","key":"3626_CR7","first-page":"100381","volume":"3","author":"SY Kim","year":"2022","unstructured":"Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, et al. Characterization of MET Exon 14 skipping alterations (in NSCLC) and identification of potential therapeutic targets using whole transcriptome sequencing. JTO Clin Res Rep. 2022;3(9):100381.","journal-title":"JTO Clin Res Rep"},{"issue":"7","key":"3626_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","volume":"34","author":"MM Awad","year":"2016","unstructured":"Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, et al. MET Exon 14 mutations in non\u2013small-cell lung cancer are associated with advanced age and stage-dependent met genomic amplification and c-met overexpression. J Clin Oncol. 2016;34(7):721\u201330.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3626_CR9","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","volume":"11","author":"AB Schrock","year":"2016","unstructured":"Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, et al. Characterization of 298 patients with lung cancer harboring MET Exon 14 skipping alterations. J Thorac Oncol. 2016;11(9):1493\u2013502.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3626_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-022-01299-z","volume":"15","author":"T Fujino","year":"2022","unstructured":"Fujino T, Suda K, Koga T, Hamada A, Ohara S, Chiba M, et al. Foretinib can overcome common on-target resistance mutations after capmatinib\/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. J Hematol Oncol. 2022;15(1):79.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"3626_CR11","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.jtho.2019.06.023","volume":"14","author":"T Fujino","year":"2019","unstructured":"Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, et al. Sensitivity and resistance of MET Exon 14 mutations in lung cancer to eight MET Tyrosine Kinase inhibitors in vitro. J Thorac Oncol. 2019;14(10):1753\u201365.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"3626_CR12","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf J, Seto T, Han J-Y, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET Exon 14\u2013Mutated or MET-Amplified non\u2013small-cell lung cancer. N Engl J Med. 2020;383(10):944\u201357.","journal-title":"N Engl J Med"},{"issue":"10","key":"3626_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in non\u2013small-cell lung cancer with MET Exon 14 skipping mutations. N Engl J Med. 2020;383(10):931\u201343.","journal-title":"N Engl J Med"},{"key":"3626_CR14","doi-asserted-by":"publisher","first-page":"1 240","DOI":"10.1186\/s12890-023-02482-9","volume":"23","author":"C Ding","year":"2023","unstructured":"Ding C, Qiu Y, Zhang J, Wei W, Gao H, Yuan Y, et al. Clinicopathological characteristics of non-small cell lung cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification. BMC Pulm Med. 2023;23:1 240.","journal-title":"BMC Pulm Med"},{"issue":"6","key":"3626_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s11523-022-00918-6","volume":"17","author":"A Fischer","year":"2022","unstructured":"Fischer A, Bankel L, Hiltbrunner S, Rechsteiner M, R\u00fcschoff JH, Rushing EJ, et al. Mutational landscape and expression of PD-L1 in Patients with non-small cell lung cancer harboring genomic alterations of the MET gene. Target Oncol. 2022;17(6):683\u201394.","journal-title":"Target Oncol"},{"issue":"9","key":"3626_CR16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jtho.2016.05.016","volume":"11","author":"S-Y Liu","year":"2016","unstructured":"Liu S-Y, Gou L-Y, Li A-N, Lou N-N, Gao H-F, Su J, et al. The unique characteristics of MET Exon 14 mutation in Chinese patients with NSCLC. J Thorac Oncol. 2016;11(9):1503\u201310.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"3626_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s12094-017-1799-7","volume":"20","author":"M Saigi","year":"2018","unstructured":"Saigi M, McLeer-Florin A, Pros E, Nadal E, Brambilla E, Sanchez-Cespedes M. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer. Clin Transl Oncol. 2018;20(7):881\u20138.","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"3626_CR18","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","volume":"22","author":"JH Tong","year":"2016","unstructured":"Tong JH, Yeung SF, Chan AW, Chung LY, Chau SL, Lung RW, et al. MET amplification and Exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22(12):3048\u201356.","journal-title":"Clin Cancer Res"},{"key":"3626_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.lungcan.2021.02.030","volume":"154","author":"SK Wong","year":"2021","unstructured":"Wong SK, Alex D, Bosdet I, Hughesman C, Karsan A, Yip S, et al. MET exon 14 skipping mutation positive non-small cell lung cancer: response to systemic therapy. Lung Cancer. 2021;154:142\u20135.","journal-title":"Lung Cancer"},{"key":"3626_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.lungcan.2020.08.009","volume":"148","author":"H Yang","year":"2020","unstructured":"Yang H, Zhou Z, Lin L, Yang M, Li C, Li Z, et al. Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers. Lung Cancer. 2020;148:113\u201321.","journal-title":"Lung Cancer"},{"issue":"2","key":"3626_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1158\/1078-0432.CCR-19-1667","volume":"26","author":"JK Rotow","year":"2020","unstructured":"Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, et al. Co-occurring Alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET Exon 14 skipping mutation-positive lung cancer. Clin Cancer Res. 2020;26(2):439\u201349.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"3626_CR22","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-19-0585","volume":"25","author":"W Fang","year":"2019","unstructured":"Fang W, Ma Y, Yin JC, Hong S, Zhou H, Wang A, et al. Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small cell lung cancer. Clin Cancer Res. 2019;25(16):5015\u201326.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"3626_CR23","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114\u201320.","journal-title":"Bioinformatics"},{"issue":"14","key":"3626_CR24","first-page":"1754","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (Oxford, England). 2009;25(14):1754\u201360.","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"9","key":"3626_CR25","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u2013303.","journal-title":"Genome Res"},{"issue":"3","key":"3626_CR26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568\u201376.","journal-title":"Genome Res"},{"issue":"689","key":"3626_CR27","doi-asserted-by":"publisher","first-page":"eabm8729","DOI":"10.1126\/scitranslmed.abm8729","volume":"15","author":"L Fairchild","year":"2023","unstructured":"Fairchild L, Whalen J, D\u2019Aco K, Wu J, Gustafson CB, Solovieff N, et al. Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing. Sci Transl Med. 2023;15(689):eabm8729.","journal-title":"Sci Transl Med"},{"issue":"7802","key":"3626_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","volume":"580","author":"JJ Chabon","year":"2020","unstructured":"Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020;580(7802):245\u201351.","journal-title":"Nature"},{"issue":"4","key":"3626_CR29","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12(4):e1004873.","journal-title":"PLoS Comput Biol"},{"issue":"18","key":"3626_CR30","first-page":"i333","volume":"28","author":"T Rausch","year":"2012","unstructured":"Rausch T, Zichner T, Schlattl A, St\u00fctz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics (Oxford, England). 2012;28(18):i333\u20139.","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"5","key":"3626_CR31","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10120-022-01308-7","volume":"25","author":"Z Lu","year":"2022","unstructured":"Lu Z, Yang S, Luo X, Shi Y, Lee J-S, Deva S, et al. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric\/gastroesophageal junction adenocarcinoma. Gastric Cancer. 2022;25(5):943\u201355.","journal-title":"Gastric Cancer"},{"issue":"1","key":"3626_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41389-023-00466-2","volume":"12","author":"Q Xu","year":"2023","unstructured":"Xu Q, Xu X, Tang H, Yan J, Li J, Bao H, et al. Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy. Oncogenesis. 2023;12(1):21.","journal-title":"Oncogenesis"},{"key":"3626_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2018.07.006","volume":"123","author":"HG Vuong","year":"2018","unstructured":"Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - a systematic review and meta-analysis. Lung Cancer. 2018;123:76\u201382.","journal-title":"Lung Cancer"},{"key":"3626_CR34","first-page":"131","volume":"10","author":"C Baldovini","year":"2019","unstructured":"Baldovini C, Rossi G, Ciarrocchi A. Approaches to tumor classification in pulmonary sarcomatoid carcinoma. Lung Cancer (Auckland, NZ). 2019;10:131\u201349.","journal-title":"Lung Cancer (Auckland, NZ)"},{"key":"3626_CR35","first-page":"35","volume":"12","author":"T Fujino","year":"2021","unstructured":"Fujino T, Suda K, Mitsudomi T. Lung cancer with MET exon 14 skipping mutation: genetic feature, current treatments, and future challenges. Lung Cancer (Auckland, NZ). 2021;12:35\u201350.","journal-title":"Lung Cancer (Auckland, NZ)"},{"issue":"2","key":"3626_CR36","first-page":"10","volume":"16","author":"R Shah","year":"2020","unstructured":"Shah R, Alex D, Xu Z. MET exon 14 skipping alterations in non-small cell lung carcinoma\u2014current understanding and therapeutic advances. Oncol Haematol Rev. 2020;16(2):10.","journal-title":"Oncol Haematol Rev"},{"issue":"6","key":"3626_CR37","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3892\/mco.2016.1057","volume":"5","author":"J Gu","year":"2016","unstructured":"Gu J, Zhou Y, Huang L, Ou W, Wu J, Li S, et al. TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: evidence from a meta-analysis. Mol Clin Oncol. 2016;5(6):705\u201313.","journal-title":"Mol Clin Oncol"},{"key":"3626_CR38","doi-asserted-by":"crossref","unstructured":"Fan Z, Zhang Q, Feng L, Wang L, Zhou X, Han J, et al. Genomic landscape and prognosis of patients with TP53 -mutated non-small cell lung cancer. 2022;10(4):188.","DOI":"10.21037\/atm-22-412"},{"key":"3626_CR39","unstructured":"Network NCC. NCCN clinical practice guidelines in oncology: non-small cell lung cancer, version 1.2026 2025 [Version 1.2026: Available from: https:\/\/www.nccn.org."},{"key":"3626_CR40","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ebiom.2019.03.023","volume":"42","author":"M Chen","year":"2019","unstructured":"Chen M, Xu Y, Zhao J, Zhong W, Zhang L, Bi Y, et al. Concurrent driver gene mutations as negative predictive factors in epidermal growth factor receptor-positive non-small cell lung cancer. eBioMedicine. 2019;42:304\u201310.","journal-title":"eBioMedicine"},{"issue":"5","key":"3626_CR41","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","volume":"182","author":"A Maynard","year":"2020","unstructured":"Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell. 2020;182(5):1232-51.e22.","journal-title":"Cell"},{"issue":"1","key":"3626_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12943-021-01331-9","volume":"20","author":"W Fang","year":"2021","unstructured":"Fang W, Jin H, Zhou H, Hong S, Ma Y, Zhang Y, et al. Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer. Mol Cancer. 2021;20(1):37.","journal-title":"Mol Cancer"},{"issue":"12","key":"3626_CR43","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1158\/2159-8290.CD-16-0686","volume":"6","author":"M Bahcall","year":"2016","unstructured":"Bahcall M, Sim T, Paweletz CP, Patel JD, Alden RS, Kuang Y, et al. Acquired METD1228V mutation and resistance to MET inhibition in lung cancer. Cancer Discov. 2016;6(12):1334\u201341.","journal-title":"Cancer Discov"},{"issue":"11","key":"3626_CR44","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","volume":"26","author":"G Recondo","year":"2020","unstructured":"Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14\u2013mutant NSCLC. Clin Cancer Res. 2020;26(11):2615\u201325.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3626_CR45","first-page":"100071","volume":"1","author":"AJ Piper-Vallillo","year":"2020","unstructured":"Piper-Vallillo AJ, Halbert BT, Rangachari D, Kobayashi SS, Costa DB. Acquired resistance to Osimertinib plus Savolitinib is mediated by MET-D1228 and MET-Y1230 mutations in EGFR-mutated MET-amplified lung cancer. JTO Clin Res Rep. 2020;1(4):100071.","journal-title":"JTO Clin Res Rep"},{"issue":"7","key":"3626_CR46","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.jtho.2017.02.017","volume":"12","author":"AB Schrock","year":"2017","unstructured":"Schrock AB, Lai A, Ali SM, Miller VA, Raez LE. Mutation of MET Y1230 as an acquired mechanism of crizotinib resistance in NSCLC with MET exon 14 skipping. J Thorac Oncol. 2017;12(7):e89\u201390.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"3626_CR47","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.jtho.2016.06.013","volume":"11","author":"RS Heist","year":"2016","unstructured":"Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, et al. Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping. J Thorac Oncol. 2016;11(8):1242\u20135.","journal-title":"J Thorac Oncol"},{"key":"3626_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100134","author":"T Fujino","year":"2021","unstructured":"Fujino T, Mitsudomi T. Acquired resistance mechanism for MET tyrosine kinase inhibitor. JTO Clin Res Rep. 2021. https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100134.","journal-title":"JTO Clin Res Rep"},{"issue":"36","key":"3626_CR49","doi-asserted-by":"publisher","first-page":"57651","DOI":"10.18632\/oncotarget.10859","volume":"7","author":"RE Henry","year":"2016","unstructured":"Henry RE, Barry ER, Castriotta L, Ladd B, Markovets A, Beran G, et al. Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. Oncotarget. 2016;7(36):57651\u201370.","journal-title":"Oncotarget"},{"issue":"6","key":"3626_CR50","first-page":"100180","volume":"2","author":"SM Lim","year":"2021","unstructured":"Lim SM, Yang S-D, Lim S, Shim HS, Cho BC. Brief report: heterogeneity of acquired resistance mechanisms to Osimertinib and Savolitinib. JTO Clin Res Rep. 2021;2(6):100180.","journal-title":"JTO Clin Res Rep"},{"issue":"24","key":"3626_CR51","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-14-1337","volume":"20","author":"M Capelletti","year":"2014","unstructured":"Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park S-I, Kim J, et al. Identification of recurrent FGFR3\u2013TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res. 2014;20(24):6551\u20138.","journal-title":"Clin Cancer Res"},{"key":"3626_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.lungcan.2017.07.006","volume":"111","author":"SI Ou","year":"2017","unstructured":"Ou SI, Horn L, Cruz M, Vafai D, Lovly CM, Spradlin A, et al. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. Lung Cancer. 2017;111:61\u20134.","journal-title":"Lung Cancer"},{"key":"3626_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010150","author":"H Bae","year":"2024","unstructured":"Bae H, Lee B, Hwang S, Lee J, Kim HS, Suh YL. Clinicopathological and molecular characteristics of IDH-wildtype glioblastoma with FGFR3::TACC3 fusion. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12010150.","journal-title":"Biomedicines"},{"issue":"3","key":"3626_CR54","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/PAS.0000000000002167","volume":"48","author":"D Suster","year":"2024","unstructured":"Suster D, Mackinnon AC, Ronen N, Mejbel HA, Harada S, Suster S. Non-small cell lung carcinoma with clear cell features and FGFR3::TACC3 gene rearrangement\u202f: clinicopathologic and next generation sequencing study of 7 cases. Am J Surg Pathol. 2024;48(3):284\u201391.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"3626_CR55","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","volume":"21","author":"LV Sequist","year":"2020","unstructured":"Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373\u201386.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3626_CR56","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1158\/1078-0432.CCR-19-3906","volume":"26","author":"I Dagogo-Jack","year":"2020","unstructured":"Dagogo-Jack I, Yoda S, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM, et al. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin Cancer Res. 2020;26(11):2535\u201345.","journal-title":"Clin Cancer Res"},{"key":"3626_CR57","doi-asserted-by":"crossref","unstructured":"Desai A, Lovly CM. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. 2023;12(3):615-28.","DOI":"10.21037\/tlcr-22-708"},{"issue":"9","key":"3626_CR58","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2217\/fon-2021-1406","volume":"18","author":"E F Smit","year":"2021","unstructured":"F Smit E, Dooms C, Raskin J, Nadal E, Tho LM, Le X, et al. INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. Future Oncol. 2021;18(9):1039\u201354.","journal-title":"Future Oncol"},{"key":"3626_CR59","doi-asserted-by":"crossref","unstructured":"Suzawa K, Offin M, Schoenfeld AJ, Plodkowski AJ, Odintsov I, Lu D, et al. Acquired MET Exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer. JCO Precis Oncol. 2019;3:1\u20138.","DOI":"10.1200\/PO.19.00011"},{"key":"3626_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112998","author":"SL Feldt","year":"2023","unstructured":"Feldt SL, Bestvina CM. The role of MET in resistance to EGFR inhibition in NSCLC: a review of mechanisms and treatment implications. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15112998.","journal-title":"Cancers"},{"issue":"4","key":"3626_CR61","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jtho.2018.12.020","volume":"14","author":"KD Davies","year":"2019","unstructured":"Davies KD, Lomboy A, Lawrence CA, Yourshaw M, Bocsi GT, Camidge DR, et al. DNA-based versus RNA-based detection of MET exon 14 skipping events in lung\u00a0cancer. J Thorac Oncol. 2019;14(4):737\u201341.","journal-title":"J Thorac Oncol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03626-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03626-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03626-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:50:01Z","timestamp":1788324601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03626-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3626"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03626-1","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed written consent was obtained from each subject or the subject\u2019s family member upon sample collection. The study adhered to the Declaration of Helsinki and was approved by the Medical Ethics Committee of Nanjing Geneseeq Medical Laboratory (NSJB-MEC-2023\u201301).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors YZ, YM and JCY are employees of Nanjing Geneseeq Technology Inc., Nanjing, China, but declare no non-financial competing interests. Other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"342"}}